Hyderabad based NATCO Pharma Limited (NSE: NATCOPHARM; BSE: 524816) has recorded consolidated total revenue of INR 583.50 Crore for the second quarter ended on 30th September, 2018, as against INR 432.20 Crore for the same period last year, reflecting a growth of 35%. The net profit for the period, on a consolidated basis, was INR 181.60 Crores as against INR 84.40 Crore same period last year, showing a growth of 115%.
During the quarter, the company has witnessed growth in the formulations business- both domestic and exports. The breakup of revenues has Formulations domestic Rs. 193.87 crores, Formulation exports including profit share/service income Rs. 247.81 crores, APIrevenues Rs. 66.81 crores, other operating / other income Rs.53.61 crores and subsidiary revenues Rs. 21.40 crores for quarter ended 30th September 2018.
Shares of NATCO PHARMA LTD. was last trading in BSE at Rs.751.5 as compared to the previous close of Rs. 779.7. The total number of shares traded during the day was 17238 in over 861 trades.
The stock hit an intraday high of Rs. 769.9 and intraday low of 751.05. The net turnover during the day was Rs. 13120667.